

TRADEMARK ASSIGNMENT COVER SHEET

Electronic Version v1.1
Stylesheet Version v1.2

ETAS ID: TM574315

SUBMISSION TYPE:	CORRECTIVE ASSIGNMENT
NATURE OF CONVEYANCE:	Corrective Assignment to correct the Receiving party data previously recorded on Reel 006602 Frame 0268. Assignor(s) hereby confirms the Corrective assignment to correct the receiving party data to replace New Jersey with Israel.
RESUBMIT DOCUMENT ID:	900543270

CONVEYING PARTY DATA

Name	Formerly	Execution Date	Entity Type
TARO PHARMACEUTICALS NORTH AMERICA, INC.		02/17/2019	Corporation:

RECEIVING PARTY DATA

Name:	TARO PHARMACEUTICAL INDUSTRIES LTD.
Street Address:	14 Hakitor Street
City:	Haifa Bay, Haifa
State/Country:	ISRAEL
Postal Code:	2624761
Entity Type:	Corporation: ISRAEL

PROPERTY NUMBERS Total: 5

Property Type	Number	Word Mark
Registration Number:	1046658	TOPICORT
Registration Number:	1570611	ORALONE
Registration Number:	1583279	OVIDE
Registration Number:	1642430	FEVERALL
Registration Number:	3950872	FEVERALL

CORRESPONDENCE DATA

Fax Number: 6095149779

Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent using a fax number, if provided; if that is unsuccessful, it will be sent via US Mail.

Phone: 609-720-5622

Email: general.ip.mailbox@sunpharma.com

Correspondent Name: SUN PHARMA

Address Line 1: 2 INDEPENDENCE WAY

Address Line 2: INTELLECTUAL PROPERTY DEPT.

Address Line 4: PRINCETON, NEW JERSEY 08540

ATTORNEY DOCKET NUMBER: TNA TRANSFER TO TPIL

NAME OF SUBMITTER:	Staci Bonin
SIGNATURE:	/Staci Bonin/
DATE SIGNED:	04/30/2020
Total Attachments: 5 source=TNA-TPIL-CorrectiveAssignment-6602-0268#page1.tif source=TNA-TPIL-CorrectiveAssignment-6602-0268#page2.tif source=TNA-TPIL-CorrectiveAssignment-6602-0268#page3.tif source=TNA-TPIL-CorrectiveAssignment-6602-0268#page4.tif source=TNA-TPIL-CorrectiveAssignment-6602-0268#page5.tif	

TRADEMARK ASSIGNMENT COVER SHEET

Electronic Version v1.1
Stylesheet Version v1.2

ETAS ID: TM516220

SUBMISSION TYPE:	NEW ASSIGNMENT		
NATURE OF CONVEYANCE:	ASSIGNMENT OF THE ENTIRE INTEREST AND THE GOODWILL		
CONVEYING PARTY DATA			
Name	Formerly	Execution Date	Entity Type
Taro Pharmaceuticals North America, Inc.		02/17/2019	Corporation: CAYMAN ISLANDS
RECEIVING PARTY DATA			
Name:	Taro Pharmaceutical Industries, Ltd.		
Street Address:	14 Hakitor Street		
City:	Haifa Bay, Haifa		
State/Country:	NEW JERSEY ISRAEL		
Postal Code:	2624761		
Entity Type:	Corporation: ISRAEL		
PROPERTY NUMBERS Total: 5			
Property Type	Number	Word Mark	
Registration Number:	1570611	ORALONE	
Registration Number:	1583279	OVIDE	
Registration Number:	1642430	FEVERALL	
Registration Number:	3950872	FEVERALL	
Registration Number:	1046658	TOPICORT	
CORRESPONDENCE DATA			
Fax Number:	6095149779		
<i>Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent using a fax number, if provided; if that is unsuccessful, it will be sent via US Mail.</i>			
Phone:	6097205394		
Email:	general.ip.mailbox@sunpharma.com		
Correspondent Name:	Sun Pharmaceutical Industries, Inc.		
Address Line 1:	2 Independence Way		
Address Line 2:	Intellectual Property Dept.		
Address Line 4:	Princeton, NEW JERSEY 08540		
ATTORNEY DOCKET NUMBER:	ORALONEOVIDEFEVERALLTOPIC		
DOMESTIC REPRESENTATIVE			
Name:	Craig Kuchii, Esq. c/o Sun Pharma		
Address Line 1:	2 Independence Way		

CH \$140.00 1570611

Address Line 2:	Intellectual Property Dept.
Address Line 4:	Princeton, NEW JERSEY 08540
NAME OF SUBMITTER:	Christine Kenedy
SIGNATURE:	/christine kenedy/
DATE SIGNED:	03/27/2019
Total Attachments: 3 source=TNA Asset Transfer - TM Assignment - TNA to TPIL (ORALONE)#page1.tif source=TNA Asset Transfer - TM Assignment - TNA to TPIL (ORALONE)#page2.tif source=TNA Asset Transfer - TM Assignment - TNA to TPIL (ORALONE)#page3.tif	

TRADEMARK ASSIGNMENT

Taro Pharmaceuticals North America, Inc. a Cayman Islands (“ASSIGNOR”) for good and valuable consideration, does hereby sell, assign, transfer and convey to Taro Pharmaceuticals Industries Ltd., an Israel Corporation.(“ASSIGNEE”), having an address at 14 Hakitor Street, Haifa Bay, Haifa Israel 2624761 its successors, assigns, and legal representatives, the ASSIGNOR’s entire rights, title and interest in and to the statutory trademark set forth in Schedule A hereto together with all common law trademarks related thereto to the subject matter disclosed therein (the “Trademark”), this Trademark Assignment is made as of April 1, 2017 (the “Effective Date”).

ASSIGNOR further assigns, transfers and conveys to ASSIGNEE all goodwill symbolized by and associated with the trademarks as used, all income, royalties and payments now or hereafter due or payable in respect thereto, and all causes of action for past, present or future infringements or violations of any of the above-assigned Trademarks and other rights, including the right to recover past and future damages for infringements or violations of such rights. ASSIGNOR also agrees to sign all documents necessary to secure any and all statutory trademarks and other right based on or related to the above associated rights, and to request issuance of all such statutory trademarks and other rights to ASSIGNEE in accordance with this Assignment


Further Assurances. ASSIGNOR agrees to execute and deliver to ASSIGNEE, upon its request, such other and further instruments of assignment and such other assistance as may be reasonably requested by ASSIGNEE in the establishment, registration, preservation and enforcement of ASSIGNEE’s rights to the foregoing.

Choice Law. This assignment shall be governed by and interpreted in accordance with laws of New York (regardless of that or any other jurisdiction’s choice of law principles).

IN WITNESS WHEREOF, ASSIGNOR and ASSIGNEE have executed and entered into this Assignment as of the Effective Date.


ASSIGNOR

Taro Pharmaceuticals North America, Inc.

By: 
Name: RICHARD PAUL WOODHOUSE
Title: GENERAL MANAGER
Date: 17/2/2019

ASSIGNEE

Taro Pharmaceuticals Industries Ltd.

By: 
Name: Stephen J. Manzano
Title: GVP, General Counsel,
Secretary & Corporate
Compliance
Date: 2/28/2019

SCHEDULE A

TRADEMARK

Country	Name	Reg. No.	Issue Date	Status
United States	ORALONE	1,570,611	12 Dec 1989	REGISTERED
United States	OVIDE	1,583,279	20 Feb 1990	REGISTERED
United States	FEVERALL	1,642,430	23 Apr 1991	REGISTERED
United States	FEVERALL	3,950,872	26 Apr 2011	REGISTERED
United States	TOPICORT	1,046,658	24 Aug 1976	REGISTERED